Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of pediatric acute lymphoblastic leukemia

A technology for acute lymphocytes and leukemia, applied in chemical instruments and methods, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, immunoglobulin, etc., can solve the problem of overall curative effect decline, tolerance reduction, Increased morbidity and other problems, to achieve the effect of eliminating the risk of recurrence and effective anti-leukemia effect

Active Publication Date: 2011-10-05
AMGEN RES (MUNICH) GMBH
View PDF7 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Problems in the management of relapsed ALL are the resistance of leukemia cells, and the reduced tolerance of patients to second rounds of therapy after first-line intensive therapy, leading to lower remission rates, higher incidence of subsequent relapses, and overall Decreased curative effect
Although recently introduced chemotherapeutic agents for refractory leukemia are available (Jeha, Semin Hematol. 46 (2009), 76-88), patients who relapse after HSCT often have chemotherapy-refractory disease and these patients are resistant to chemotherapy-related disease. very sensitive to toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of pediatric acute lymphoblastic leukemia
  • Treatment of pediatric acute lymphoblastic leukemia
  • Treatment of pediatric acute lymphoblastic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0162] 1. CD19xCD3 bispecific single chain antibody

[0163] WO 99 / 54440 describes the production, expression and cytotoxic activity of a CD19xCD3 bispecific single chain antibody. The corresponding amino acid and nucleic acid sequences of the CD19xCD3 bispecific single chain antibody are shown in SED ID NO.1 and 2, respectively. The VH and VL regions of the CD3-binding domain of the CD19xCD3 bispecific single-chain antibody are shown in SED ID NO.7-10, respectively, while the VH and VL regions of the CD19-binding domain of the CD19xCD3 bispecific Shown in SED ID NO.3-6.

[0164] 2. Lymphocyte phenotype analysis and chimerism analysis

[0165] Before, during, and after treatment with the CD19xCD3 bispecific single-chain antibody, blood was collected from patients using collection tubes containing EDTA for lymphocyte phenotype analysis and chimerism analysis. The absolute number of lymphocytes in the blood sample was determined by performing differential blood analysis (diff...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.

Description

technical field [0001] The present invention relates to a method for treating, improving or eliminating childhood acute lymphoblastic leukemia (ALL), the method comprising administering a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in need thereof. Background technique [0002] With current treatment of childhood ALL, the event-free survival rate is about 75%. So, relapses are still frequent. Problems in the management of relapsed ALL are the resistance of leukemia cells, and the reduced tolerance of patients to second rounds of therapy after first-line intensive therapy, leading to lower remission rates, higher incidence of subsequent relapses, and overall Efficacy decreased. Intensive combination chemotherapy is thus currently necessary to induce a second complete remission. Depending on various prognostic factors, remission may be maintained with chemotherapy and brain irradiation alone or with ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C07K16/46
CPCC07K16/2803C07K16/2809C07K16/468C07K16/3061C07K2317/56A61K2039/505A61P35/00A61P35/02A61K39/395
Inventor 格哈德·祖格迈尔
Owner AMGEN RES (MUNICH) GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com